for Veterans and the Public
Frequently Asked Questions
Q: Is it true the FDA approved new drugs for hepatitis C?
Yes. In late 2013, the US Food and Drug Administration (FDA) approved two new drugs for hepatitis C.
Simeprevir (Olysio) is a tablet to be taken once per day along with pegylated interferon and ribavirin for patients with genotype 1.
Sofosbuvir (Sovaldi) is a tablet to be taken once per day.
- with pegylated interferon and ribavirin for genotype 1
- with ribavirin only (no interferon) for genotype 2 and 3
- in some patients with genotype 1 who are not able to take interferon, some can take sofosbuvir with ribavirin (without interferon).
The combination of simeprevir and sofosbuvir (used together) is not FDA approved. However, in very limited situations, it may be considered by your provider. This regimen consists of simeprevir with sofosbuvir and with or without ribavirin. No interferon is used in this regimen. Again this is used only in a limited number of situations.
There are also multiple other new drugs under investigation and some of which may be approved in 2014-2015.